In Brief This Week: Exact Sciences, Hologic; Myriad Genetics; Cepheid; Bio-Rad Laboratories; Ambry Genetics; GNS Healthcare; Horizon Discovery; Interleukin Genetics; Kreatech; BioSignatures | GenomeWeb

NEW YORK (GenomeWeb News) – Exact Sciences said in its 10-K filing with the US Securities and Exchange Commission this week that in December it entered into an amendment to a licensing agreement pursuant to which Hologic granted the company a non-exclusive worldwide license to certain Hologic patents within the field of any disease or condition within, related to, or affecting the gastrointestinal tract and/or appended mucosal surfaces. The amendment is to an agreement the firms signed in 2009.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?